Biologics
-
Biologics
Ivory Dentin Graft Earns CE Mark
It's the first and only dentin graft, according to the company.Sam Brusco, Associate Editor 09.21.22
-
Biologics
FDA OKs Ventris Medical's Amplify Putty, Bone Graft Extender
Amplify is a synthetic bone graft biomaterial designed to optimize cell proliferation and bone formation.Sam Brusco, Associate Editor 09.13.22
-
Biologics
Ortho Regenerative Tech Changes Name to ChitogenX
Better represents company's proprietary tech platform expanded applications beyond orthopedics.Sam Brusco, Associate Editor 09.07.22
-
Biologics
Study: BONESUPPORT’s CERAMENT G Can Help Save Infected Limbs
Data show effectiveness of antibiotic-eluting bone graft substitute in managing bone infections.Michael Barbella, Managing Editor 08.19.22
-
Biologics
Six Orthopedic Firms En Route to Significant Market Disruption
The ODT Editors have spotlighted six companies outside the Top 10 they feel are making an impact on the device sector.08.12.22
-
Biologics
GreenBone Signs Distribution Agreement for its Regenerative Scaffold
Abiogen Pharma SpA will market the 3D bone substitute in Italy.Michael Barbella, Managing Editor 08.05.22
-
Biologics
Orthofix, CGBio Ink Licensing Deal for Novosis Bone Graft
The two companies will collaborate to clinically develop and commercialize recombinant human bone morphogenic protein-2 (rhBMP-2).Sam Brusco, Associate Editor 08.02.22
-
Biologics
MiMedx Group Forms Regenerative Medicine Scientific Advisory Board
Will provide guidance on the company’s regenerative medicine clinical pipeline initiatives and support its focus on placental biologics innovation.Charles Sternberg, Associate Editor 07.29.22
-
Biologics | Spine/Neurology
NuVasive Touts Positive Results of Bioactive Interbody Study
Attrax Putty and Modulus XLIF implant achieved complete bone bridging in 97.8% of patients.Sam Brusco, Associate Editor 07.26.22
-
Biologics
Expanded FDA Nod for Bone Solutions' Mg OSTEOINJECT
Expands the orthobiologic's indication to use as an adjunct to hardwareSam Brusco, Associate Editor 07.13.22
-
Biologics
First Patient Enrolled in BioRestorative Therapies' Chronic Lumbar Disc Disease Trial
Up to 99 eligible patients will be randomized at up to 15 U.S. centers to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.Michael Barbella, Managing Editor 07.05.22
-
Biologics
Researchers Discover Novel Patching Material for Bone Defects
Bio-responsive ceramic could aid in the recovery of bone defects and help improve quality of life.Charles Sternberg, Associate Editor 06.27.22
-
Biologics
Isto Biologics Rolls Out Influx Fibrant
A line of functional constructs derived from 100% cortical allograft.Charles Sternberg, Associate Editor 06.23.22
-
Biologics | Extremities
Ortho RTI Begins Rotator Cuff Repair Trial
4 clinical sites are currently recruiting and screening patients for randomization in the Phase I/II studySam Brusco, Associate Editor 06.13.22
-
Biologics
FDA OKs Royal Biologics' MAXX-BMC Bone Marrow Aspirate Concentration System
The company also began commercial launch in the U.S.Sam Brusco, Associate Editor 06.01.22
-
Biologics
SeaSpine Launches OsteoTorrent DBM Franchise
The putties aim to improve osteoinductive potential and shelf life.Sam Brusco, Associate Editor 05.04.22
-
Biologics
Orthofix, MTF Biologics Expand Partnership
The collaboration extends Orthofix’s exclusive marketing rights to the Trinity allograft line through 2032.Michael Barbella, Managing Editor 05.03.22
-
Biologics
Royal Biologics Debuts Advanced Bone Grafting, Fusion Kit
Advanced - Cell features three technologies that promote key components for bone fusion and enhanced autologous healing.Michael Barbella, Managing Editor 04.28.22
-
Biologics
Isto Biologics Acquires Allograft Firm TheraCell
Will introduce TheraFuze DBF (demineralized bone fiber) tech to Isto’s Influx line.Sam Brusco, Associate Editor 04.06.22
-
Biologics
OSSIOfiber Implants Gain 3rd FDA Clearance in 4 Months
Company prepares to expand access to bio-integrative orthopedic fixation tech portfolio.Sam Brusco, Associate Editor 03.29.22
